Strategic launch planning: familiar framework, new mindset

While much of life has been turned on its head over the last year, in the world of strategic launch planning, in some ways, not that much has changed.

This may sound counter-intuitive given the various COVID-19-related challenges faced by those tasked with launching a new medicine over the past year. But for those currently taking a product through phase 3, the critical tasks that lie ahead, such as developing an early brand plan, evolving it into a pre-launch plan and ensuring organisational readiness for launch, are essentially unchanged.

Strategic planning remains strategic planning – it’s about understanding the landscape that you are operating in and working out the best path forwards, towards your goals. When viewed in that context, COVID-19 and its impact become one of many aspects of the current landscape that need to be considered.

While the basic framework of strategic launch planning has not changed, it should be acknowledged that the fabric of many aspects within it has. Outlined below are some of these changes, along with key questions that strategic launch planning should address:

• Targeting patients: the patient journey may have changed; established market assumptions may no longer hold true. How well can you describe your priority patients at launch?
• Targeting customers: HCPs and payers may have additional responsibilities and new priorities, especially if hospital based. Are you clear on which customers you will focus on at launch and what their needs are?
• Market engagement: greater local flexibility may be needed in terms of adapting global/ regional strategies. Do you understand what is important at a local market level? What will make HCPs and patients in the markets want to use your drug?
• Differentiation and positioning: the dynamic/ switch market may be less accessible; historical product uptake patterns may be less realistic. Do you understand the value that your product offers customers and patients? How will you communicate this and drive product uptake?
• Organisational readiness: obtaining internal buy-in in a virtual environment can be challenging. Onboarding and training processes for sales reps and MSLs have changed and digital customer engagement models are now essential. Do you have internal alignment behind your launch plan? Have you left sufficient time for launch excellence and resource planning?
• Scheduling and accountability: planning may need to start earlier to allow for the additional complexity. Is there a clear and shared understanding of who will be doing what, when?